Wednesday, January 25, 2017

BRIEF-Beigene initiates global Phase III trial of the BTK inhibitor BGB-3111

* Beigene initiates global Phase III trial of the BTK

inhibitor BGB-3111 in Waldenström's Macroglobulinemia

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)